Know Cancer

forgot password

A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function

Phase 1
18 Years
Not Enrolling
Renal Impairment

Thank you

Trial Information

A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function

Inclusion Criteria:

- A patient must meet all of the following inclusion criteria to be eligible for
enrollment in this study:

1. Has histologically or cytologically proven advanced solid tumors for which no
standard therapy exists.

2. Has provided written informed consent.

3. Is 18 years of age or older.

4. Is able to take medications orally.

5. Has Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to ≤ 2
Appendix A,ECOG Performance Status).

6. Has adequate organ function as defined by the following criteria:

1. Transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times the upper limit of
normal(ULN). If liver function abnormalities are due to underlying
malignancy, then AST(SGOT) and ALT (SGPT) may be ≤ 5 times ULN.

2. Total serum bilirubin ≤ 1.5 times ULN.

3. Absolute granulocyte count ≥ 1,500/mm3 (ie, ≥ 1.5 x 109/L by International
Units [IU]).

4. Has a platelet count ≥ 100,000/mm3 (IU: ≥ 100 x 109/L).

5. Has a hemoglobin value of ≥ 9.0 g/dL.

7. Is willing and able to comply with scheduled visits, treatment plan, laboratory
tests, and other study procedures.

3.3.2 Exclusion Criteria

Exclude a patient from this study if he/she does not fulfill the inclusion criteria, or if
any of the following conditions are observed:

1. Has had treatment with any of the following within the specified time frame prior to
study drug administration:

1. Any investigational agent received either concurrently or within the last 30

2. Previous therapy for malignancy within 21 days, including any chemotherapy,
immunotherapy, biologic or hormonal therapy (6 weeks for nitrosoureas or

3. Previous radiotherapy within 14 days.

4. Current enrollment in another clinical trial.

2. Has a serious illness or medical condition(s) including, but not limited to, the

1. Myocardial infarction within the last 6 months, severe/unstable angina,
congestive heart failure (New York Heart Association [NYHA] Class III or IV,
Appendix E, NYHA Classification).

2. Known (at the time of entry) gastrointestinal disorder, including malabsorption,
chronic nausea, vomiting, or diarrhea present to the extent that it might
interfere with oral intake and absorption of the study medication.

3. Known brain metastasis.

4. Known leptomeningeal metastases.

5. Requires hemodialysis.

6. Known human immunodeficiency virus (HIV) or acquired immunodeficiency
syndrome(AIDS)-related illness.

7. Other severe acute or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or
study drug administration, or may interfere with the interpretation of study
results, and in the judgment of the Investigator would make the patient
inappropriate for entry into this study.

3. Is receiving a concomitant treatment with drugs interacting with S-1. The following
drugs are prohibited because there may be an interaction with S-1:

1. Sorivudine, uracil, dipyridamole, cimetidine and folinic acid (may enhance S-1

2. Allopurinol (may diminish S-1 activity).

3. Phenytoin (S-1 may enhance phenytoin activity).

4. Flucytosine, a fluorinated pyrimidine antifungal agent (may enhance S-1 and
flucytosine activity).

5. Pilocarpine (may inhibit CYP2A6 activity).

4. Has known sensitivity to 5-FU.

5. Is a pregnant or lactating female.

6. Is a patient with reproductive potential who refuses to use an adequate means of

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To provide specific dosing recommendations for S-1 in patients with renal impairment based on the PK of S-1 and its components after single dose and steady state conditions.

Outcome Time Frame:

The Pharmacokinetic Phase (Part 1) of the study will last 24 days.

Safety Issue:



United States: Food and Drug Administration

Study ID:




Start Date:

February 2006

Completion Date:

September 2010

Related Keywords:

  • Renal Impairment
  • Renal Impairment
  • Renal Insufficiency



Washington University School of Medicine Saint Louis, Missouri  63110
Yale Cancer Center New Haven, Connecticut  06520-8028
The Institute for Drug Development San Antonio, Texas  78229
Premiere Oncology Santa Monica, California  90404
Premiere Oncology of Arizona Scottsdale, Arizona  85260
LAC/USC Medical Center Los Angeles, California  90033
University of Kentucky/Division of Hematology/Oncology and Blood Marrow Transplantation Lexington, Kentucky  40536
University of Maryland/Greenebaum Cancer Center Baltimore, Maryland  21201
Cancer Research & Treatment Center/University of New Mexico Albuquerque, New Mexico  87131